Accelerate Net Debt To E B I T D A from 2010 to 2025
| AXDX Stock | USD 0.70 0.16 18.60% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (1.37) | Current Value (1.30) | Quarterly Volatility 1.84565849 |
Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 13.8 M or Selling General Administrative of 16.3 M, as well as many indicators such as Price To Sales Ratio of 2.27, Dividend Yield of 2.0E-4 or Days Sales Outstanding of 60.38. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.
Accelerate | Net Debt To E B I T D A |
Latest Accelerate Diagnostics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Accelerate Diagnostics over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Accelerate Diagnostics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Accelerate Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Accelerate Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 0.24 | |
| Coefficient Of Variation | 757.78 | |
| Mean Deviation | 1.52 | |
| Median | (0.54) | |
| Standard Deviation | 1.85 | |
| Sample Variance | 3.41 | |
| Range | 6.4424 | |
| R-Value | (0.69) | |
| Mean Square Error | 1.90 | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (0.27) | |
| Total Sum of Squares | 51.10 |
Accelerate Net Debt To E B I T D A History
About Accelerate Diagnostics Financial Statements
Accelerate Diagnostics investors use historical fundamental indicators, such as Accelerate Diagnostics' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | (1.37) | (1.30) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.